The basis of Fang and colleagues’ hypothesis is as follows: (a) increase in ACE2 activity in cardiovascular diseases (also in other diseases, e.g., diabetes) and (b) increase in ACE2 activity in experimental models under the influence of ACE inhibitors and angiotensin 2 receptor blockers [5]. This evidence concerns the gene ACE2 and diabetes mellitus.